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Complex DNA repair mechanisms evolved in cells toprotect the integrity of genetic information from ex-
ogenous and endogenous damage. Distinct restoring path-
ways emerged for base and nucleotide excision, mismatch
by insertion, deletion or base substitution, recombination
repair, and translesion synthesis.1 With better understand-
ing of these molecular processes, opportunities come out
that therapeutically exploit the differences between tumor
and normal cells in their capacity to restore DNA damage.
SUMMARY OF PRESENTATIONS
DNA Repair Biomarkers
Dr. George R. Simon used the example of the excision
repair cross-complementation 1 gene (ERCC1) as a valid
predictive marker in clinical research. The product of the
ERCC1 gene is a key enzyme in nucleotide excision repair,
which eliminates platinum DNA adducts.1 When used as a
biomarker, ERCC1 was shown to predict for platinum sensi-
tivity. Several clinical studies were presented with ERCC1 as
a selective biomarker: Adjuvant Trial IFCT0704 in nonsqua-
mous stages II and IIIA where in the EGFR/wild-type arm
ERCC1 presence selected patients to observation, whereas its
absence led to cisplatin pemetrexed therapy. Another trial to
be conducted by the Southwest Oncology Group is a pilot
proof of concept study with pharmacogenomic-directed ad-
juvant therapy in stage I NSCLC. Besides ERCC1, ribonul-
ceotide reductase M1 (RRM1) was used in an Automated
Quantitative Analysis (AQUA)-based assay. RRM1 encodes
two subunits of ribonucleoside-diphosphate reductase, an
enzyme essential for the production of deoxyribonucleotides
before DNA synthesis in S phase of dividing cells and
predicts for sensitivity to gemcitabine.2 The MADeIT trial
stands for a phase II study on the use of molecular analyses-
based customized chemotherapy in patients with stage IV/IIIB
(malignant pleural effusion) NSCLC. With 59% 12-month
overall survival, the study suggests that ERCC1 and RRM1-
based molecular analysis applied in clinical setting has sur-
vival benefits superior to previous studies with simple com-
binations of agents used here (docetaxel, navelbine,
gemcitabine, and carboplatin, Figure 1).
A phase III study is under way with the MADeIT
algorithm built-in in one arm compared with standard doublet
of carboplatin and gemcitabine. In early-stage disease, high
ERCC1 identifies a subset of patients who are less likely to
relapse and derive no additional benefit from platinum-based
chemotherapy. Low ERCC1 on the other hand identifies a
subset with poor prognosis but with benefit from platinum-
based treatment.
Another well-studied repair marker is the tumor sup-
pressor BRCA1 (Breast Cancer Type 1 gene/protein). Muta-
tions of BRCA1 and 2 strongly predispose individuals to
cancer because they cause a deficiency in DNA repair
through homologous recombinantion. As a predictive bi-
omarker, BRCA1 may, besides sensitivity to platinum, also
identify a cohort of patients that respond to docetaxel.
Poly(Adenosine Diphosphate-Ribose)
Polymerase Inhibitors
Poly(adenosine diphosphate-ribose) polymerase (PARP)
facilitates base excision repair.3 Inhibition of members of the
PARP family can selectively kill BRCA1 and BRCA2-deficient
cells. The benzimidazole derivative ABT-888 is a potent inhib-
itor of PARP1 and 2. In his presentation, Dr. Suresh Ramal-
ingam reported that in preclinical models, ABT-888 potentiated
the effect of temozolomide, cisplatin, cyclophosphamide, iri-
nothecan, and radiation therapy. An exploratory phase 0 study
with ABT-888 established the target assay feasibility with no
treatment-related adverse events reported so far. The bioavail-
ability of the drug is 50% with oral administration. ABT-888
has demonstrated tolerability as a single agent and with other
drugs in early-phase clinical studies. Its combinations with
carboplatin and paclitaxel are feasible, and a phase II study in
advanced NSCLC is under development.
Another PARP inhibitor, AG-014699, is a small mol-
ecule IV agent that has demonstrated activity against PARP
by potentiating antitumor effects of radiation in preclinical
models, by enhancement of drugs that break DNA strands
(e.g., temozolomide and topoisomerase inhibitors) and by
inhibiting PARP enzyme activity in peripheral blood in a PD
phase 1 trial. Dr. Mace Rothenberg from Pfizer reported that
AG-014699 has shown promising activity as a cytotoxic
potentiating agent when used in conjunction with temozol-
amide in patients with metastatic melanoma and as a single
agent in women with BRCA-positive breast and ovarian
cancer. At present, AG 014699 is being examined in a phase
II proof of principle IIR study in known carriers of a BRCA1
or BRCA2 mutation with metastatic breast or ovarian cancer.
About 30% of NSCLC carry a BRCA mutation, and this loss
of function is associated with a worse prognosis in patients
with resected disease. AG-014699 is being considered for a
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phase II trial in patients with metastatic NSCLC with BRCA
mutation. Considerations whether BRCA status alone can
stand as an independent prediction test are still ongoing.
Aurora Kinase A Inhibitor
Aurora kinases A, B, and C are involved in cell cycle
regulation through centrosome function, bipolar spindle as-
sembly, and chromosomal segregation process.4 In his re-
view, Dr. David Mauro from Merck reported that Aurora A
kinase is required for entry into a progression through mito-
sis, and it can induce oncogenic transformation. Overexpres-
sion of Aurora A was detected in breast, lung, pancreatic,
bladder, esophageal, ovarian, renal, head and neck cancers. It
is amplified in breast, colon, bladder, head and neck cancers.
Aurora A can be suppressed by RNAi that leads to tumor
growth suppression and enhanced taxane sensitivity. Known
functional interactions between Aurora A and p53 and cell-
line data suggest greatest efficacy will be in p53 context.
Aurora A is a preclinically validated target for therapeutic
intervention as its inhibition in combination with taxanes
produces robust synergy over taxanes alone in multiple cell
lines and xenograft models. Efficacy in monotherapy was
also demonstrated in some xenograft models. An inhibitor
MK-5108 was successfully used in preclinical cell line and
animal models together with predictive biomarkers pHH3
and qPCR signature. Aurora A kinase and p53 interact at
multiple levels. Preclinical data with MK-5108 and other
Aurora A inhibitors suggest p53-negative tumors may be
more sensitive to Aurora A inhibitors than p53-positive
tumors. A phase I, open label, randomized, two panel
(monotherapy and combination) dose escalation trial of
MK-5108 alone or with docetaxel in adult patients with
locally advanced or metastatic solid tumors was reported.
Study endpoints include safety, PK/PD, and maximum
tolerated dose relationships, and objective tumor response
in monotherapy only.
WEE1 Inhibitor
The protein WEE1 catalyzes inhibitory tyrosine phos-
phorylation of CDC2/cyclin B kinase and seems to coordinate
the transition between DNA replication and mitosis by pro-
tecting the nucleus from cytoplasmically activated CDC2
kinase.5 Preclinical data indicate that inhibition of WEE1
may abrogate G2 checkpoint arrest in the selective sensitiza-
tion of certain tumor cells. A new WEE1 inhibitor MK-1775
was reported by Dr. Mauro as a p53 context-specific DNA
damage sensitizer. It specifically sensitizes p53-negative
cells to DNA damage by abrogation of the G2 checkpoint
as shown in in vitro studies with gemcitabine, carboplati-
num, and doxorubicin. Encouraged by preclinical studies,
a three-arm phase I trial was designed with the use of
gemcitabine, cisplatin, or carboplatin in combination with
MK-1775 in patients with p53-deficient tumors. The study
is almost completed, and phase II studies will commence
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FIGURE 1. MADeIT trial concept (Simon, printed with
permission).
FIGURE 2. Current technologies
for detecting of p53 mutation: Im-
munohistochemistry vs. DNA se-
quencing analysis. (Mauro, printed
with permission).
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in the second half of 2009. Of question remains the choice
of assays measuring p53 because available tests have still
to reach desirable requirements.
Glutathione Disulfide-Mimetic
Even though this agent is not involved in DNA repair,
it is discussed here briefly. Dr. Thomas Lynch introduced a
novel redox modulating agent NO-002. The drug alters cel-
lular redox status and activity of redox-sensitive proteins,
resulting in pleiotropic effects on cell functions such as
activation of signaling pathways, cytoskeletal changes, and al-
tered cytokine production. A Russian phase II study in chemona-
ive advanced NSCLC showed 63% 1-year survival in the
NOV-002 plus cisplatin versus 17% in cisplatin alone. A
significant increase in tolerance to chemotherapy with 66%
more cycles received was observed in the combination arm.
A US phase I/II trial in patients with advanced NSCLC used
paclitaxel and carboplatin with or without NOV-002. Objec-
tive tumor response was seen in 69% of patients with NOV-
002 against 33% in the chemotherapy alone arm. A pivotal
phase III study in advanced NSCLC is being conducted in an
international consortium with overall survival as the primary
efficacy endpoint. It is an open label randomized trial of
carboplatinum/paclitaxel  NOV-002. Standard doses of
carboplatinum/paclitaxel are combined with NOV-002 and
given IV on day 1 then SC on day 1 to 21. The event-driven
final analysis is expected by the end of 2009. In other cancers, a
completed phase II US study in platinum-resistant ovarian can-
cer was reported where the median progression-free survival
lasted 15.4 weeks (nearly 2 historical control). A clinical
benefit was observed in 60% of evaluable patients. There is an
ongoing phase II neoadjuvant trial in breast cancer in combina-
tion with chemotherapy, also in the United States.
SUMMARY
Information about the molecular processes associated
with DNA repair has led to the development of pharmacog-
enomic biomarkers for customized therapy on one hand and
to the design of small molecules that target DNA repair mech-
anisms on the other. Both areas are rapidly evolving and produce
promising leads. A number of phase II and phase III clinical
trials are under way that may move the field forward. There is
still a need to improve existing biomarker assays for their
optimal accuracy and practicality of use. Examples are tests for
p53 or ERCC1 where immunochemistry, mutation analysis,
and/or reverse-transcriptase polymerase chain reaction show
mutually exclusive advantages and drawbacks (Figure 2).
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